DAFTAR PUSTAKA

Ahmad, Z., Brown, C. M., Patel, A. K., Ryan, A. F., Ongkeko, R., & Doherty, J. K. (2010). Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. *Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology*, *31*(3), 460–466. https://doi.org/10.1097/MAO.0B013E3181D2777F

Aizer, A. A., Abedalthagafi, M., Linda Bi, W., Horvath, M. C., Arvold, N. D., Al-Mefty, O., Lee, E. Q., Nayak, L., Rinne, M. L., Norden, A. D., Reardon, D. A., Wen, P. Y., Ligon, K. L., Ligon, A. H., Beroukhim, R., Dunn, I. F., Santagata, S., & Alexander, B. M. (2016). A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. *Neuro-Oncology*, *18*(2), 269–274. https://doi.org/10.1093/NEUONC/NOV177

Alfthan, K., Heiska, L., Grönholm, M., Renkema, G. H., & Carpén, O. (2004). Cyclic AMP-dependent Protein Kinase Phosphorylates Merlin at Serine 518 Independently of p21-activated Kinase and Promotes Merlin-Ezrin Heterodimerization. *Journal of Biological Chemistry*, *279*(18), 18559–18566. https://doi.org/10.1074/jbc.M313916200

Al-Mefty, O., Kersh, J. E., Routh, A., & Smith, R. R. (1990). The long-term side effects of radiation therapy for benign brain tumors in adults. *Journal of Neurosurgery*, *73*(4), 502–512. https://doi.org/10.3171/JNS.1990.73.4.0502

Apriyani, V. K. (2021). *FAKTOR RISIKO MENINGIOMA ORBITOKRANIAL PADA WANITA PENGGUNA KONTRASEPSI HORMONAL*.

Baldi, I., Engelhardt, J., Bonnet, C., Bauchet, L., Berteaud, E., Grüber, A., & Loiseau, H. (2018). Epidemiology of meningiomas. *Neurochirurgie*, *64*(1), 5–14. https://doi.org/10.1016/J.NEUCHI.2014.05.006

Benson, V. S., Kirichek, O., Beral, V., & Green, J. (2015). Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. *International Journal of Cancer*, *136*(10), 2369–2377. https://doi.org/10.1002/IJC.29274

Benson, V. S., Pirie, K., Green, J., Casabonne, D., & Beral, V. (2008). Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. *British Journal of Cancer*, *99*(1), 185–190. https://doi.org/10.1038/SJ.BJC.6604445

Brastianos, P. K., Horowitz, P. M., Santagata, S., Jones, R. T., Mckenna, A., Getz, G., Ligon, K. L., Palescandolo, E., Van Hummelen, P., Ducar, M. D., Raza, A., Sunkavalli, A., Macconaill, L. E., Stemmer-Rachamimov, A. O., Louis, D. N., Hahn, W. C., Dunn, I. F., & Beroukhim, R. (2013). Genomic sequencing of meningiomas

identifies oncogenic SMO and AKT1 mutations. *Nature Genetics*, *45*(3), 285–289. https://doi.org/10.1038/NG.2526

Buerki, R. A., Horbinski, C. M., Kruser, T., Horowitz, P. M., James, C. D., & Lukas, R. V. (2018). An overview of meningiomas. *Future Oncology*, *14*(21), 2161. https://doi.org/10.2217/FON-2018-0006

Bush, M. L., Oblinger, J., Brendel, V., Santarelli, G., Huang, J., Akhmametyeva, E. M., Burns, S. S., Wheeler, J., Davis, J., Yates, C. W., Chaudhury, A. R., Kulp, S., Chen, C. S., Chang, L. S., Welling, D. B., & Jacob, A. (2011). AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. *Neuro-Oncology*, *13*(9), 983–999. https://doi.org/10.1093/NEUONC/NOR072

Carroll, S. L. (2011). Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. *Acta Neuropathologica 2011 123:3*, *123*(3), 321–348. https://doi.org/10.1007/S00401-011-0928-6

Clark, V. E., Erson-Omay, E. Z., Serin, A., Yin, J., Cotney, J., Özduman, K., Avşar, T., Li, J., Murray, P. B., Henegariu, O., Yilmaz, S., Günel, J. M., Carrión-Grant, G., Yilmaz, B., Grady, C., Tanrikulu, B., Bakircioğlu, M., Kaymakçalan, H., Caglayan, A. O., … Günel, M. (2013). Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. *Science (New York, N.Y.)*, *339*(6123), 1077–1080. https://doi.org/10.1126/SCIENCE.1233009

Delgado-López, P. D., Cubo-Delgado, E., González-Bernal, J. J., & Martín-Alonso, J. (2020). A Practical Overview on the Molecular Biology of Meningioma. *Current Neurology and Neuroscience Reports*, *20*(12). https://doi.org/10.1007/S11910-020-01084-W

Deng, J., Hua, L., Han, T., Tian, M., Wang, D., Tang, H., Sun, S., Chen, H., Cheng, H., Zhang, T., Xie, Q., Wan, L., Zhu, H., & Gong, Y. (2020). The CREB-binding protein inhibitor ICG-001: a promising therapeutic strategy in sporadic meningioma with NF2 mutations. *Neuro-Oncology Advances*, *2*(1), 1–11. https://doi.org/10.1093/NOAJNL/VDZ055

Evers, S., Verbaan, D., Sanchez, E., & Peerdeman, S. (2015). 3D Volumetric Measurement of Neurofibromatosis Type 2-Associated Meningiomas: Association Between Tumor Location and Growth Rate. *World Neurosurgery*, *84*(4), 1062–1069. https://doi.org/10.1016/J.WNEU.2015.05.068

Garcia-Ruíz, G., Flores-Espinosa, P., Preciado-Martínez, E., Bermejo-Martínez, L., Espejel-Nuñez, A., Estrada-Gutierrez, G., Maida-Claros, R., Flores-Pliego, A., & Zaga-Clavellina, V. (2015). In vitro progesterone modulation on bacterial endotoxin-induced production of IL-1β, TNFα, IL-6, IL-8, IL-10, MIP-1α, and MMP-9 in pre-labor human term placenta. *Reproductive Biology and Endocrinology : RB&E*, *13*(1). https://doi.org/10.1186/S12958-015-0111-3

Goldbrunner, R., Minniti, G., Preusser, M., Jenkinson, M. D., Sallabanda, K., Houdart, E., von Deimling, A., Stavrinou, P., Lefranc, F., Lund-Johansen, M., Moyal, E. C. J., Brandsma, D., Henriksson, R., Soffietti, R., & Weller, M. (2016). EANO guidelines for the diagnosis and treatment of meningiomas. *The Lancet. Oncology*, *17*(9), e383–e391. https://doi.org/10.1016/S1470-2045(16)30321-7

Gusella, J. F., Ramesh, V., MacCollin, M., & Jacoby, L. B. (1999). Merlin: the neurofibromatosis 2 tumor suppressor. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, *1423*(2), M29–M36. https://doi.org/10.1016/S0304-419X(99)00005-0

Hanemann, C. O. (2008). Magic but treatable? Tumours due to loss of Merlin. *Brain*, *131*(3), 606–615. https://doi.org/10.1093/BRAIN/AWM249

Huang, M., Manzano, G. R., & Levi, A. D. (2023). Meningioma. *Tumors of the Spinal Canal*, 39–51. https://doi.org/10.1007/978-3-030-55096-7_2

Huntoon, K., Toland, A. M. S., & Dahiya, S. (2020). Meningioma: A Review of Clinicopathological and Molecular Aspects. *Frontiers in Oncology*, *10*. https://doi.org/10.3389/FONC.2020.579599

James, M. F., Han, S., Polizzano, C., Plotkin, S. R., Manning, B. D., Stemmer-Rachamimov, A. O., Gusella, J. F., & Ramesh, V. (2023). NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth. *Https://Doi.Org/10.1128/MCB.01581-08*, *29*(15), 4250–4261. https://doi.org/10.1128/MCB.01581-08

Korhonen, K., Salminen, T., Raitanen, J., Auvinen, A., Isola, J., & Haapasalo, H. (2006). Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. *Journal of Neuro-Oncology*, *80*(1), 1–7. https://doi.org/10.1007/S11060-006-9146-9

Laulajainen, M., Melikova, M., Muranen, T., Carpén, O., & Grönholm, M. (2012). Distinct overlapping sequences at the carboxy-terminus of merlin regulate its tumour suppressor and morphogenic activity. *Journal of Cellular and Molecular Medicine*, *16*(9), 2161. https://doi.org/10.1111/J.1582-4934.2012.01525.X

Lee, E. J., Park, J. H., Park, E. S., & Kim, J. H. (2017). "Wait-and-See" Strategies for Newly Diagnosed Intracranial Meningiomas Based on the Risk of Future Observation Failure. *World Neurosurgery*, *107*, 604–611. https://doi.org/10.1016/J.WNEU.2017.08.060

Lee, S., Karas, P. J., Hadley, C. C., Bayley V., J. C., Basit Khan, A., Jalali, A., Sweeney, A. D., Klisch, T. J., & Patel, A. J. (2019). The Role of Merlin/NF2 Loss in Meningioma Biology. *Cancers*, *11*(11). https://doi.org/10.3390/CANCERS11111633

Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016).

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica*, *131*(6), 803–820. https://doi.org/10.1007/S00401-016-1545-1/TABLES/5

Marosi, C., Hassler, M., Roessler, K., Reni, M., Sant, M., Mazza, E., & Vecht, C. (2008). Meningioma. *Critical Reviews in Oncology/Hematology*, *67*(2), 153–171. https://doi.org/10.1016/J.CRITREVONC.2008.01.010

Mawrin, C., Sasse, T., Kirches, E., Kropf, S., Schneider, T., Grimm, C., Pambor, C., Vorwerk, C. K., Firsching, R., Lendeckel, U., & Dietzmann, K. (2005). Different Activation of Mitogen-Activated Protein Kinase and Akt Signaling Is Associated with Aggressive Phenotype of Human Meningiomas. *Clinical Cancer Research*, *11*(11), 4074–4082. https://doi.org/10.1158/1078-0432.CCR-04-2550

McClatchey, A. I. (2007). Neurofibromatosis. *Https://Doi.Org/10.1146/Annurev.Pathol.2.010506.091940*, *2*, 191–216. https://doi.org/10.1146/ANNUREV.PATHOL.2.010506.091940

Meling, T. R., Da Broi, M., Scheie, D., Helseth, E., & Smoll, N. R. (2019). Meningioma Surgery-Are We Making Progress? *World Neurosurgery*, *125*, e205–e213. https://doi.org/10.1016/J.WNEU.2019.01.042

Mezmezian, M. B., Dopazo, V., Deforel, M. L., & Puzzo, M. (2017). Immunohistochemical Expression of Progesterone Receptors in Nonmeningothelial Central Nervous System Tumors. *Applied Immunohistochemistry and Molecular Morphology*, *25*(6), 439–444. https://doi.org/10.1097/PAI.0000000000000318

Michaud, D. S., Gallo, V., Schlehofer, B., Tjønneland, A., Olsen, A., Overvad, K., Dahm, C. C., Kaaks, R., Lukanova, A., Boeing, H., Schütze, M., Trichopoulou, A., Bamia, C., Kyrozis, A., Sacerdote, C., Agnoli, C., Palli, D., Tumino, R., Mattiello, A., … Riboli, E. (2010). Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. *Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology*, *19*(10), 2562. https://doi.org/10.1158/1055-9965.EPI-10-0447

Muskens, I. S., Wu, A. H., Porcel, J., Cheng, I., Le Marchand, L., Wiemels, J. L., & Setiawan, V. W. (2019). Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort. *Neuro-Oncology*, *21*(4), 498–507. https://doi.org/10.1093/NEUONC/NOZ005

Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., & Baradaran, B. (2019). The relation between PI3K/AKT signalling pathway and cancer. *Gene*, *698*, 120–128. https://doi.org/10.1016/J.GENE.2019.02.076

Ogasawara, C., Philbrick, B. D., & Adamson, D. C. (2021). Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions.

Biomedicines 2021, Vol. 9, Page 319, *9*(3), 319. https://doi.org/10.3390/BIOMEDICINES9030319

Okada, T., Lopez-Lago, M., & Giancotti, F. G. (2005). Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. *Journal of Cell Biology*, *171*(2), 361–371. https://doi.org/10.1083/JCB.200503165

Ongaratti, B. R., Silva, C. B. O., Trott, G., Haag, T., Leães, C. G. S., Ferreira, N. P., Oliveira, M. C., & Pereira-Lima, J. F. S. (2016). Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence. *Brazilian Journal of Medical and Biological Research*, *49*(4). https://doi.org/10.1590/1414-431X20155125

Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2022). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. *Neuro-Oncology*, *24*(Suppl 5), v1–v95. https://doi.org/10.1093/NEUONC/NOAC202

Pavelin, S., Bečić, K., Forempoher, G., Tomić, S., Čapkun, V., Drmić-Hofman, I., Mrklić, I., Lušić, I., & Pogorelić, Z. (2014). The significance of immunohistochemical expression of merlin, ki-67, and p53 in meningiomas. *Applied Immunohistochemistry and Molecular Morphology*, *22*(1), 46–49. https://doi.org/10.1097/PAI.0B013E318289F490

Petrilli, A. M., & Fernández-Valle, C. (2016). Role of Merlin/NF2 inactivation in tumor biology. *Oncogene*, *35*(5), 537–548. https://doi.org/10.1038/ONC.2015.125

Phillips, L. E., Koepsell, T. D., Van Belle, G., Kukull, W. A., Gehrels, J. A., & Longstreth, W. T. (2002). History of head trauma and risk of intracranial meningioma: Population-based case-control study. *Neurology*, *58*(12), 1849–1852. https://doi.org/10.1212/WNL.58.12.1849

Preusser, M., Brastianos, P. K., & Mawrin, C. (2018). Advances in meningioma genetics: novel therapeutic opportunities. *Nature Reviews Neurology 2018 14:2*, *14*(2), 106–115. https://doi.org/10.1038/nrneurol.2017.168

Qi, Z. Y., Shao, C., Huang, Y. L., Hui, G. Z., Zhou, Y. X., & Wang, Z. (2013). Reproductive and Exogenous Hormone Factors in Relation to Risk of Meningioma in Women: A Meta-Analysis. *PLoS ONE*, *8*(12). https://doi.org/10.1371/JOURNAL.PONE.0083261

Ramnani D., & Cuevas-Ocampo A. (2014). *Meningiomas*. https://www.webpathology.com/case.asp?case=637

Reuss, D. E., Piro, R. M., Jones, D. T. W., Simon, M., Ketter, R., Kool, M., Becker, A., Sahm, F., Pusch, S., Meyer, J., Hagenlocher, C., Schweizer, L., Capper, D., Kickingereder, P., Mucha, J., Koelsche, C., Jäger, N., Santarius, T., Tarpey, P. S., … Von Deimling, A. (2013). Secretory meningiomas are defined by combined KLF4

K409Q and TRAF7 mutations. *Acta Neuropathologica*, *125*(3), 351–358. https://doi.org/10.1007/S00401-013-1093-X

Rong, R., Tang, X., Gutmann, D. H., & Ye, K. (2004). Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. *Proceedings of the National Academy of Sciences of the United States of America*, *101*(52), 18200–18205. https://doi.org/10.1073/PNAS.0405971102/SUPPL_FILE/5971FIG5.PDF

Rouleau, G. A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C., Plougastel, B., Pulst, S. M., Lenoir, G., Bijlsma, E., Fashold, R., Dumanski, J., Jong, P. De, Parry, D., Eldrige, R., Aurias, A., … Thomas, G. (1993). Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. *Nature 1993 363:6429*, *363*(6429), 515–521. https://doi.org/10.1038/363515a0

Samadi, N., & Ahmadi, S. A. (2007). Meningioma: A Clinicopathological Evaluation. *The Malaysian Journal of Medical Sciences : MJMS*, *14*(1), 46. /pmc/articles/PMC3351217/

Shaw, R. J., Paez, J. G., Curto, M., Yaktine, A., Pruitt, W. M., Saotome, I., O'Bryan, J. P., Gupta, V., Ratner, N., Der, C. J., Jacks, T., & McClatchey, A. I. (2001). The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. *Developmental Cell*, *1*(1), 63–72. https://doi.org/10.1016/S1534-5807(01)00009-0

Shibuya, M. (2015). Pathology and Molecular Genetics of Meningioma: Recent Advances. *Neurologia Medico-Chirurgica*, *55*(1), 14. https://doi.org/10.2176/NMC.RA.2014-0233

Shimizu, T., Seto, A., Maita, N., Hamada, K., Tsukita, S., Tsukita, S., & Hakoshima, T. (2002). Structural Basis for Neurofibromatosis Type 2. *Journal of Biological Chemistry*, *277*(12), 10332–10336. https://doi.org/10.1074/jbc.m109979200

Shu, X., Jiang, Y., Wen, T., Lu, S., Yao, L., & Meng, F. (2019). Association of hormone replacement therapy with increased risk of meningioma in women: A hospital-based multicenter study with propensity score matching. *Asia-Pacific Journal of Clinical Oncology*, *15*(5), e147–e153. https://doi.org/10.1111/AJCO.13138

Stamenkovic, I., & Yu, Q. (2010). Merlin, a "Magic" Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival. *Current Protein & Peptide Science*, *11*(6), 471. https://doi.org/10.2174/138920310791824011

Supartoto, A., Sasongko, M. B., Respatika, D., Mahayana, I. T., Pawiroranu, S., Kusnanto, H., Sakti, D. H., Nurlaila, P. S., Heriyanto, D. S., & Haryana, S. M. (2019). Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females. *Frontiers in Oncology*, *8*(JAN). https://doi.org/10.3389/FONC.2018.00651

Takahashi, H., Cornish, A. J., Sud, A., Law, P. J., Disney-Hogg, L., Calvocoressi, L., Lu, L., Hansen, H. M., Smirnov, I., Walsh, K. M., Schramm, J., Hoffmann, P., Nöthen, M. M., Jöckel, K. H., Schildkraut, J. M., Simon, M., Bondy, M., Wrensch, M., Wiemels, J. L., … Houlston, R. S. (2019). Mendelian randomization provides support for obesity as a risk factor for meningioma. *Scientific Reports*, *9*(1). https://doi.org/10.1038/S41598-018-36186-6

TikooS, A., VargaS, M., Rameshl, V., Gusellal, J., & Marutatll, H. (1994). An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). *THE JOURNAL OF BIOUK~ICAL CHEMISTRY*, *269*(38), 23387–23390. https://doi.org/10.1016/S0021-9258(17)31525-9

Torp, S. H., Solheim, O., & Skjulsvik, A. J. (2022). The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know—a minireview. *Acta Neurochirurgica*, *164*(9), 2453. https://doi.org/10.1007/S00701-022-05301-Y

Trofatter, J. A., Maccoiiin, M. M., Rutter, J. L., Murreil, J. R., Duyao, M. P., Parry, D. M., Eidridge, R., Kiey, N., Nlenon, A. G., Pulaski, K., Haase, V. H., Ambrose, C. M., Munroe, D., Bove, C., Haines, J. L., Martuza, R. L., Macdonald, M. E., Seizinger, B. R., Short, ' M Priscilla, … Gusella', J. F. (1993). A Novel Moesin-, Ezrin-, Radixin-like Gene Is a Candidate for the Neurofibromatosis 2 Tumor Suppressor. *Cell*, *72*.

Umansky, F., Shoshan, Y., Rosenthal, G., Fraifeld, S., & Spektor, S. (2008). Radiation-induced meningioma. *Neurosurgical Focus*, *24*(5). https://doi.org/10.3171/FOC/2008/24/5/E7

Watt, K. I., Harvey, K. F., & Gregorevic, P. (2017). Regulation of tissue growth by the mammalian Hippo signaling pathway. *Frontiers in Physiology*, *8*(NOV), 302368. https://doi.org/10.3389/FPHYS.2017.00942/BIBTEX

Wellenreuther, R., Kraus, J. A., Lenartz, D., Menon, A. G., Schramm, J., Louis, D. N., Ramesh, V., Gusella, J. F., Wiestler, O. D., & Von Deimling, A. (1995). Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. *The American Journal of Pathology*, *146*(4), 827. /pmc/articles/PMC1869258/?report=abstract

Weller, M., Roth, P., Sahm, F., Burghardt, I., Schuknecht, B., Rushing, E. J., Regli, L., Lindemann, J. P., & Von Deimling, A. (2017). Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. *JNCI: Journal of the National Cancer Institute*, *109*(3). https://doi.org/10.1093/JNCI/DJW320

Wiemels, J., Wrensch, M., & Claus, E. B. (2010). Epidemiology and etiology of meningioma. *Journal of Neuro-Oncology*, *99*(3), 307–314. https://doi.org/10.1007/S11060-010-0386-3/FIGURES/1

Winter, R. C., Antunes, A. C. M., & De Oliveira, F. H. (2020). The relationship between vascular endothelial growth factor and histological grade in intracranial meningioma. *Surgical Neurology International*, *11*(328). https://doi.org/10.25259/SNI_528_2020

Wu, W., Zhou, Y., Wang, Y., Liu, L., Lou, J., Deng, Y., Zhao, P., & Shao, A. (2020). Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma. *Frontiers in Oncology*, *10*, 1633. https://doi.org/10.3389/FONC.2020.01633/BIBTEX

Zhao, L., Zhao, W., Hou, Y., Wen, C., Wang, J., Wu, P., & Guo, Z. (2020). An Overview of Managements in Meningiomas. *Frontiers in Oncology*, *10*, 1523. https://doi.org/10.3389/FONC.2020.01523/BIBTEX